Become A Featured Company

New Canadian Study Shows Widespread Drugged Driving

Robin Lefferts

August 14th, 2018

Exclusive, News, Top News

Statistics Canada conducted a survey this spring and found that 14% of cannabis users with a driver’s license reported driving within two hours of cannabis use at least once in the prior three months, while 5% of the overall population reported riding in vehicles driven by someone who had used cannabis in the two hours prior to driving. At the same time, Canada is set to approve the use of a roadside saliva test for drug use that has demonstrated accuracy issues, especially in cold conditions. There are also concerns about the relatively invasive and time-consuming test violating citizens’ Charter rights, which could lead to lengthy legal challenges. The test appears to be an imperfect solution to a pressing public safety issue made all the more urgent in light of Canada’s pending nationwide legalization of adult-use cannabis.

Cannabix Technologies Inc. (CSE: BLO) (OTC: BLOZF) (FRA: 8CT) has been diligently developing its Cannabix Marijuana Breathalyzer, steadily advancing the device toward the eventual goal of entering the market with an accurate, non-invasive and convenient way to test for marijuana use.

Breath vs. Saliva

Many of the issues surrounding the saliva test center on the invasiveness of the procedure (police swab the suspects mouth for a couple of minutes) as well as the time needed (10-15 minutes from the beginning of the procedure to the results). Courts have already decided that the timely harvesting of a person’s breath, and the quick results of the test, are in line with individuals’ rights to privacy and due process. Upon implementation of the new saliva test, many expect court challenges based on at least those two issues. Substantial concerns have also been raised around police safety as officers would be required to be in close physical proximity to drivers for about ten minutes while the saliva testing was taking place. Considering the precedent set by alcohol breathalyzers, Cannabix’s Marijuana Breathalyzer would likely avoid those hurdles should the technology be approved.

Another concern is the accuracy of the tests. A study of 300 Norwegian drivers tested with both the saliva test and a blood test showed a discrepancy of about 14% between the two methods. With the blood test considered more accurate, the saliva test returned about 14% false-negatives as well as about 14% false positives. In Australia, authorities estimated the saliva test’s accuracy at about 66%. Accuracy is impaired in cold and hot weather as well, with the saliva test’s temperature range listed between four and 40 degrees Celsius. Anyone familiar with Canadian winters knows tests that don’t consistently work in even mildly cold weather pose problems.

Cannabix is using mass spectrometry (MS) related technology known as field asymmetric waveform ion mobility spectrometry (FAIMS) to ensure accuracy in all conditions. Without getting too technical, MS is the gold standard technology for determining the molecular makeup of sample substances, relying on each molecule’s unique mass-to-charge ratio. Ion-mobility spectrometry identifies substances by the mobility of the ions within. The two can be combined to present a very accurate profile of the sample, especially when calibrated to seek out specific molecules such as THC or its metabolites.

Cannabix has been developing its prototype breathalyzer for research and pilot testing and eventual commercial use. Over the last several months, the company has been developing a device that can achieve a high level of sensitivity to detect THC and related metabolized forms of THC in order to establish a recent use of cannabis from breath samples. The goal is to provide law enforcement and workplaces with a reliable, non-invasive device to help determine a driver’s cannabis impairment.

Disclaimer

The above article is sponsored content. Emerging Growth LLC, which owns CannabisFN.com and CFN Media, has been hired to create awareness. Please follow the link below to view our full disclosure outlining our compensation: https://cannabisfn.com/legal-disclaimer/

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Robin Lefferts

Robin Lefferts has been involved in the legal cannabis industry since 2012, sometimes as an active participant and always as an interested observer.

Network Partners

Follow Us on Social Media

LinkedIn

About CFN Media Group

CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.

Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.

Copyright © Accelerize Inc. · All Rights Reserved · Privacy Policy · Legal Disclaimer

loading